Urology News
-
Infection Control Resources to Safeguard Patients and Building Occupants from Acinetobacter and Other Pathogens
The Centers for Disease Control and Prevention describe Acinetobacter as a group of bacteria commonly found in the environment in places like soil and water. While there are many types, the most frequent cause of infections in humans is known as Acinetobacter baumannii. Those most at risk of infection according to the CDC include patients in hospitals, especially those who: · are ...
-
Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) CKD affects up to 40% of people with T1D A quarter of people with CKD associated with T1D progress to end-stage kidney disease Only limited treatment options are available for people with CKD and ...
By Bayer AG
-
The Dutch Government Elects to Sponsor the ENFORCE Trial - A Fully Funded RCT That Includes the Nanoknife System for Prostate Treatment
We are pleased to offer congratulations to Professor Jurgen Fütterer and his team at Radboud University Medical Centre in the Netherlands, for having successfully secured €3.8 million from the Dutch National Health Care Institute and ZonMw towards the ENFORCE trial, a fully funded Randomised Controled Trial for Focal Therapy which incorporates the NanoKnife System as a treatment option ...
-
With Policy Support, the Market for Surgical Robots Grows
Recently, the Ministry of Industry and Information Technology, the National Health Commission and other 17 departments jointly issued the "robot" application action implementation plan to encourage the development of surgery, auxiliary examination, auxiliary rounds, intensive care, rehabilitation and other medical robot products, "robot The "robot" has ushered in a new round of development ...
-
Press release: High quality, cost effective surgical retractor is welcomed by leading US hospital group
JUNE Medical is delighted to announce a new agreement with a major US hospital group to supply the award-winning Galaxy II® self-retaining surgical retractors to over 1,600 hospitals in the US, commencing April 15, 2023. This game-changing device radically improves the safety and ease of surgical retraction for both patients and medical staff; its ergonomic design transforms the way in which ...
-
miR Scientific and Leonie Hill Capital Announce Collaboration to Introduce Breakthrough Urine Liquid Biopsy Prostate Cancer Test in Singapore
High demand seen for effective disease management platform for second most common cancer in Singaporean men NEW YORK and SINGAPORE, March 28, 2022 /PRNewswire/ -- miR Scientific, a New York-based healthcare company dedicated to transforming global cancer management, and Leonie Hill Capital, a Singapore-based organization focused on large-scale, sophisticated healthcare access and distribution, ...
-
TURP Primer - Transurethral resection of the prostate
The TURP Primer is especially geared towards all urologists and their assistants who are interested in learning how to perform TURP or who are already performing TURP and would like to deepen their understanding of the physical and technical fundamentals. This primer is available in German language and provides an overview of the most important TURP developments of the past 20 years to today. In ...
-
Guidelines for the diagnosis, treatment and metaphylaxis of urolithiasis
Updated reprint – exclusively available from FARCO-PHARMA The Urinary Stones Working Group of the Academy of German Urologists, the Deutsche Gesellschaft für Urologie e. V. [German Society of Urology], and the Berufsverband der Deutschen Urologen e. V. [Professional Association of German Urologists], under the direction of Prof. Dr. med. Thomas Knoll, have re-issued the S2k Guideline ...
-
FARCO-PHARMA initiates sales in the U.S.
The U.S. Food and Drug Administration recently completed its regulatory inspection of the production site in Berlin and issued FARCO-PHARMA approval for the marketing of a sterile lubricant in disposable syringes in the United States. FARCO-PHARMA has been producing and selling the sterile catheter lubricant under the brand name GLYDO® on the U.S. market since October 2014. Medicinal ...
-
Lipella Pharma Sees Positive Results for LP-10 Phase 2a Trial
Lipella Pharmaceuticals Inc. said it saw positive top-line results from its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis. The biotechnology company said its next step will be to communicate with the Food and Drug Administration on the study’s results and the pathway forward to seeking regulatory approval ...
-
Globalization - Ezisurg Medical’s Staplers Approved in Saudi Arabia
Ezisurg Medical’s staplers have been approved by the Saudi Food and Drug Authority recently. This is the latest achievement made in Ezisurg Medical’s international sector, soon after finishing CE and FDA certification or ...
-
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported Newly presented data offered additional insight into the SKYLARK Study and further demonstrated the rapid improvements in depressive symptoms observed in the clinical ...
-
CD Bioparticles Introduces Hydrophilic Coatings for Medical Applications
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, recently introduced hydrophilic coatings and related services for medical applications, which can be used within interventional medical devices of the cardiovascular, circulatory, nervous, urinary, and vascular system. Functional medical coatings are a class of interface materials applied to the ...
-
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients - - Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients with Severe Renal Impairment, Including Those on Hemodialysis - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 6, 2022-- Alnylam ...
-
I Lost One of the Most Vital Organs - Prostate Cancer Patient Stories
Prostate cancer is the most common type of cancer in men. Every year this diagnosis is made about 900 thousand times, in developed countries the disease affects up to 14% of the entire male population with oncology due to longer life expectancy. We spoke with adult prostate cancer survivors. ...
-
Announcement – New Urological AI Tool for 3D Reconstruction of the Ureter
Innovative technology utilizes 2D fluoroscopic images and reconstructs an accurate 3D model of the ureter for planning and guidance during ureteroplasty. RSIP Vision, a leader in driving innovation for medical imaging through advanced AI and computer vision solutions, announces today a new tool for 3D reconstruction of the ureter. This tool transforms 2D fluoroscopic images of the ureter into a ...
By RSIP Vision
-
FDA Approves Taiho’s LYTGOBI® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
LYTGOBI (pronounced “light-GOH-bee”) delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary analysis of the pivotal clinical trial. LYTGOBI covalently binds to FGFR2 and inhibits the signaling pathway. The other approved FGFR inhibitors are reversible ATP-competitive inhibitors. LYTGOBI previously received breakthrough, orphan drug ...
-
Creative Medical Technology Announces Positive Top-Line Results for StemSpine Pilot Study
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive two-year follow-up data for the Company's StemSpine® pilot study, showing significant efficacy of the StemSpine® ...
-
New partner Continentia Association
In January 2017 we signed a collaboration agreement with Continentia Association. The Association, created by a group of specialists in the field of urology, focused on research of incontinence-related diseases and professional training in this field. Incorporating their experience and extensive knowledge is a great value to us. Dr. José Emilio Batista, president of the Association, is ...
-
Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine Study
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, today announced the peer reviewed publication of positive, two-year follow-up data for the Company's StemSpine® study, showing significant efficacy of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you